Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Corcept Therapeutics Incorporated due to allegations of materially misleading business information issued to the investing public [1] Company Summary - Corcept Therapeutics Incorporated is facing scrutiny for potentially misleading information that may have affected its securities [1] - Shareholders who purchased Corcept securities may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement [1]

NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Corcept Theraepeutics Incorporated (NASDAQ: CORT)?Did you lose money in your investment in Corcept Theraepeutics Incorporated?Do you want to discuss your rights? Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating whether Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) violated federal securities laws. If you own Corcept stock and would lik ...

Core Insights - Shares of Corcept Therapeutics experienced a significant decline of 16% following a corrected "complete response letter" from the U.S. Food and Drug Administration (FDA) [1] - The FDA's letter indicated that the agency had previously warned the company on several occasions regarding compliance issues [1] Company Summary - Corcept Therapeutics faced a notable drop in stock value due to regulatory challenges highlighted by the FDA [1] - The FDA's communication suggests ongoing concerns about the company's adherence to regulatory standards, which could impact future operations and market perception [1]

BOSTON, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Corcept Therapeutics Inc. (Nasdaq: CORT) for potential securities law violations. Investors who have lost money in their Corcept Therapeutics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/cort. What is this all about? Shares of Corcept Therapeutics fell 16% in pre-market trading on January 30, after a report highlighted language in th ...

Core Viewpoint - DJS Law Group is investigating claims against Corcept Therapeutics for potential violations of securities laws following the FDA's Complete Response Letter regarding the company's New Drug Application for relacorilant, which led to a significant drop in share price [1][2]. Investigation Details - The investigation centers on whether Corcept made misleading statements or failed to disclose critical information to investors [2]. - On December 31, 2026, Corcept announced that the FDA issued a Complete Response Letter for relacorilant, despite acknowledging that the pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial provided confirmatory evidence [2]. - Following the FDA's announcement, Corcept's shares plummeted by more than 50% [2]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, aiming to enhance investor returns through effective advocacy [4].

Core Insights - Corcept Therapeutics Incorporated is under investigation for potential violations of federal securities laws following a Complete Response Letter (CRL) from the FDA regarding its new drug application for relacorilant [1][2] - The FDA's decision was based on the need for additional evidence of effectiveness despite acknowledging previous trial results [2] - Following the announcement, Corcept's stock price experienced a significant drop of $31.42, equating to a 44.76% decrease, marking a new 52-week low [2][3] Company Overview - Corcept Therapeutics focuses on developing treatments for patients with conditions related to hypercortisolism, specifically hypertension [1] - The company has faced challenges in gaining FDA approval for its drug relacorilant, which has implications for its market position and investor confidence [2] Market Reaction - The stock price decline to $38.78 per share reflects investor concerns over the FDA's decision and the potential impact on the company's future [2][3] - The drop in stock price indicates a significant loss of value for shareholders, prompting investigations into the company's compliance with securities laws [1][3]

Core Insights - Corcept Therapeutics' shares increased by 13.7% following the announcement that the phase III ROSELLA study met its overall survival primary endpoint for relacorilant in combination with nab-paclitaxel in treating platinum-resistant ovarian cancer [1] Study Results - The ROSELLA study demonstrated a 35% reduction in the risk of death for patients treated with relacorilant plus nab-paclitaxel compared to those receiving nab-paclitaxel alone [2] - Patients receiving the combination therapy achieved a median overall survival (OS) of 16 months, compared to 11.9 months for those on nab-paclitaxel alone [3] - The combination treatment was well tolerated, with a safety profile consistent with existing data, providing clinical benefits without increasing safety risks [3] Regulatory Developments - The FDA accepted the new drug application (NDA) for relacorilant in combination with nab-paclitaxel, with a decision expected on July 11, 2026 [6][9] - Corcept submitted a marketing authorization application to the European Medicines Agency for relacorilant, with a decision anticipated later in 2026 [9] Market Context - Corcept's shares have declined by 40% over the past six months, contrasting with a 2.9% decline in the industry [4] - The company previously faced a setback when the FDA issued a complete response letter regarding the NDA for relacorilant in treating hypercortisolism, which negatively impacted investor sentiment [11][12] Financial Performance - Korlym, Corcept's sole-marketed drug for Cushing's syndrome, generated sales of $559.3 million in the first nine months of 2025, reflecting a year-over-year increase of approximately 13.4% [13]

Core Insights - Corcept Therapeutics Incorporated (NASDAQ:CORT) is focused on developing medications that modulate cortisol effects to treat severe disorders, including oncologic conditions [1] - H.C. Wainwright upgraded CORT's stock to "Buy" and raised its price target from $90 to $105, with the stock priced at approximately $41.87 at the time of the announcement [1][5] Stock Performance - Following the upgrade, CORT's stock has seen a notable increase, currently priced at $41.30, reflecting a 13.74% increase with a change of $4.99 [3][5] - The stock has fluctuated between a low of $40.46 and a high of $52.84 during today's trading [3] - Over the past year, the stock reached a high of $117.33 and a low of $32.99 [3] Clinical Trial Results - The upgrade coincides with significant developments, particularly the successful results from the ROSELLA Phase 3 trial, which tested the combination of relacorilant and nab-paclitaxel for treating platinum-resistant ovarian cancer [2] - The trial demonstrated a 35% reduction in the risk of death for patients receiving the combination therapy [2][5] - The combination therapy was well-tolerated, with adverse events similar to those experienced with nab-paclitaxel monotherapy [4] Market Capitalization and Trading Volume - Corcept's market capitalization is approximately $4.34 billion, with a trading volume of 5,304,058 shares [4]

Core Insights - Corcept Therapeutics is focused on developing drugs for severe metabolic and oncologic disorders, particularly in cortisol modulation therapies [1] - The company faces competition from Teva Pharmaceuticals and Mylan in similar therapeutic areas [1] Stock Performance - Analyst Swayampakula Ramakanth from H.C. Wainwright set a new price target of $105 for CORT, indicating a potential increase of approximately 46.8% from the current price of $41.47 [2][6] - Corcept's stock has seen a significant increase, with trading volume reaching over 3 million shares following successful results from the ROSELLA Phase 3 trial [3][6] - The current stock price is $41.61, reflecting a 14.60% increase with a change of $5.30, and the stock has fluctuated between a low of $40.46 and a high of $43.50 during the day [5] Clinical Trial Results - The ROSELLA Phase 3 trial tested relacorilant and nab-paclitaxel in treating platinum-resistant ovarian cancer, showing a 35% reduction in the risk of death for patients receiving the combination therapy [3][6] - The median overall survival for patients treated with relacorilant was 16 months, compared to 11.9 months for those on nab-paclitaxel alone, marking an improvement of 4.1 months [4][6] - The combination therapy was well-tolerated, with adverse events similar to those experienced with nab-paclitaxel monotherapy [4] Market Capitalization - Corcept's market capitalization stands at approximately $4.38 billion, with today's trading volume at 4,189,821 shares on the NASDAQ exchange [5]

Core Insights - Corcept Medical (CORT.US) announced that its pivotal Phase 3 trial ROSELLA achieved the primary endpoint of overall survival (OS) [1] - The trial evaluated the efficacy of the selective cortisol modulator relacorilant in combination with nab-paclitaxel for treating platinum-resistant ovarian cancer patients [1] - The FDA has accepted the New Drug Application (NDA) for relacorilant, with a PDUFA date set for July 11, 2026, and the EMA is also reviewing the marketing authorization application (MAA) for the same indication [1] Efficacy and Safety - Patients receiving relacorilant in combination with nab-paclitaxel experienced a 35% reduction in the risk of death compared to those receiving nab-paclitaxel alone (HR=0.65, p=0.0004) [1] - The median OS for patients treated with relacorilant was 16.0 months, compared to 11.9 months for those on nab-paclitaxel alone, representing a difference of 4.1 months [1] - The combination treatment demonstrated good tolerability, with adverse events being comparable in type, frequency, and severity to those in the nab-paclitaxel monotherapy group [2] Additional Findings - The ROSELLA trial also met the primary endpoint of progression-free survival (PFS) improvement, confirmed by blinded independent central review (BICR) [2] - Patients receiving the combination therapy had a 30% lower risk of disease progression compared to those receiving nab-paclitaxel alone (HR=0.70, p=0.008) [2] - Relacorilant is an oral selective glucocorticoid receptor (GR) antagonist that modulates cortisol activity without binding to other hormone receptors [2] - Corcept is advancing the development of relacorilant for ovarian cancer and various other serious conditions, including endogenous Cushing's syndrome, endometrial cancer, cervical cancer, pancreatic cancer, and prostate cancer [2] - The drug has received orphan drug designation from the FDA and the European Commission for the treatment of Cushing's syndrome and ovarian cancer [2]